MN-ECOLAB
13.3.2024 09:01:27 CET | Business Wire | Press release
Ecolab Inc., a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and the resources vital to life, today announced the successful sourcing of enough clean electricity to power 100% of its European operations, thanks to the completion of a windfarm project with the global renewable energy company, Low Carbon.
In 2022, Ecolab and Low Carbon entered into an agreement to develop the Mörknässkogen windfarm, located on the west coast of Finland near the city of Vaasa. Now, the windfarm has reached full commercial operation, and its 30MW capacity will generate approximately 100GWh of electricity annually. That’s enough to power 30,000 homes and avoid 20,000 tonnes of CO2e per year.
By sourcing the power produced by the windfarm, Ecolab will cover 100% of the electricity used across all its European sites, including 15 major offices, 26 manufacturing facilities and seven RD&E centers. This achievement elevates the company’s global renewable electricity sourcing level to 80%, marking a significant stride in Ecolab’s journey to achieving 100% renewable electricity globally by 2030, a key component of Ecolab’s 2030 Impact Goals.
"We believe that truly sustainable companies deliver on both their financial and environmental goals,” said Christophe Beck, Chairman and CEO, Ecolab. “By achieving this milestone in Europe, we'll be sourcing the renewable energy needed to power our operations and as we electrify our vehicle fleet. These efforts support our continued growth and ability to serve customers, all while moving us closer to our 2030 Impact Goals and a 100% positive future."
“We are delighted to see Low Carbon’s first Finnish wind project enter operations, which is a major milestone as we look to increase the amount of renewable energy capacity globally,” said John Isherwood, Managing Director at Low Carbon. “The 10-year PPA with our Ecolab partners underlines our shared vision for a world that is powered by renewables and will make a vital contribution to Finland’s supply of clean, secure energy.”
This latest renewable power milestone builds on Ecolab’s progress in North America, where the company reached 100% renewable electricity in 2020 as a result of its 2018 investment in the Mesquite Star windfarm in Texas and 2015 investment in a local community solar garden project in Minnesota.
As the electrical grids in major markets become greener, Ecolab’s virtual Power Purchase Agreements in North America and Europe account for the company’s transition to electric vehicles. Ecolab recently announced accelerated efforts to electrify its sales and service fleet in North America by 2030.
Ecolab’s Power Purchase Agreements and its other initiatives put the company on pace to achieve its renewable electricity targets by 2030. That’s well ahead of guidelines outlined by RE100, a global corporate initiative focused on achieving 100% renewable electricity by 2050, of which Ecolab is a member.
For more information on Ecolab’s 2030 Impact Goals, visit ecolab.com/corporate-responsibility/2030-impact-goals. For more information on Ecolab’s commitment to operating sustainably, visit ecolab.com/corporate-responsibility.
About Ecolab
A trusted partner for millions of customers, Ecolab (NYSE:ECL) is a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and the resources vital to life. Building on a century of innovation, Ecolab has annual sales of $15 billion, employs more than 48,000 associates and operates in more than 170 countries around the world. The company delivers comprehensive science-based solutions, data-driven insights and world-class service to advance food safety, maintain clean and safe environments, and optimize water and energy use. Ecolab’s innovative solutions improve operational efficiencies and sustainability for customers in the food, healthcare, life sciences, hospitality and industrial markets.
Follow us on LinkedIn @Ecolab, Twitter @Ecolab, Instagram @Ecolab_Inc and Facebook @Ecolab.
About Low Carbon
Low Carbon creates large-scale renewable energy to fight climate change. We’re building a net-zero energy company that will protect the planet for future generations. This defining purpose drives us to deliver for our communities, investors, and the environment. We are a long-standing certified B-Corporation and recognized as a gold standard for our environmental impact.
We invest in, develop, and operate solar, wind, energy storage, and energy from waste projects across the UK, Europe, and North America. We’re contributing to the world’s move to 100% renewable energy by creating and operating 20GW of new capacity by 2030.
We have more than 8GW in new renewables in development right now across the globe.
Low Carbon is on a mission. Together, we will power tomorrow.
(ECL-C)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240313546541/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
Unpack ’26 sommerrejsetrends: Flere vælger indenlandske rejser, når de tænker mere bevidst over deres rejsevalg21.5.2026 12:35:00 CEST | Pressemeddelelse
Rejsebranchens førende databrevne trendrapport lancerer sin første sommerudgave nogensinde – Unpack ’26 Summer: The Trends in Travel I dag har Hotels.com udgivet Unpack ’26 Summer: The Trends in Travel, den nyeste udgave af virksomhedens førende trendrapport i rejsebranchen, som viser, hvordan rejseadfærd former sommerens rejsevalg. Efterspørgslen på indenlandske rejser præger sommerens ferieplanlægning. Interessen på sociale medier for indenlandske ferier er globalt steget med 77% sammenlignet med sidste år, og 44% af danske rejsende planlægger en indenlandsk rejse denne sommer*. Fra store sportsbegivenheder og koncerter til rejser inspireret af film og tv bygger Unpack ’26 Summer på indsigter fra den årlige hovedrapport Unpack ’26: The Trends in Travel™ for at fremhæve, hvor rejsende tager hen denne sommer. HHver tendens bygger på førstehåndsdata fra Hotels.com® kombineret med indsigter fra rejsende og overvågning af sociale medier. “Denne sommer bliver der stadig rejst – men på nye
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
